A new study published today by The Universities of Manchester, Nottingham and University College London says that the New Medicine Service in England has improved patients' adherence medicines adherence by 10%. It states this has created short term savings of over £75 million in the first five years of the service and will lead to savings of over half a billion - £517.6 million - in the longer term.
Sandra Gidley, Chair of RPS England said: "“This research provides a resounding endorsement of the benefits to patient care and to the NHS of the New Medicine Service. Better health outcomes combined with significant savings to the NHS budget is the holy grail of medicine optimisation.
"The list of medicines covered by the service should now be extended to cover all long term conditions including mental health issues so that more patients can benefit in a structured way from the support a pharmacist can offer. We’d also like to see more patients referred into the service by primary or secondary care providers to ensure the service is used as widely as possible. All patients prescribed new medication should be encouraged to take part in the New Medicine Service by their prescriber."
According to previous research from the University of Nottingham, the costs to NHS England of non-adherence is over £930 million per year in just five diseases: asthma, type 2 diabetes, high cholesterol/coronary heart disease, hypertension and schizophrenia.
Read the RPS briefings on 12 different conditions to help pharmacists deliver medicines optimisation in their daily practice and and the quick reference guide on medicines adherence for further information.